This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Compugen Presents At American Association Of Cancer Research Special Conference On Tumor Immunology

Speaking today at the American Association of Cancer Research Special Conference on Tumor Immunology in Miami, Florida, Dr. Ofer Levy, Senior Scientist at Compugen Ltd., presented data supporting the therapeutic potential of CGEN-15001T and CGEN-15022, proteins discovered by Compugen, as immune checkpoint targets for cancer immunotherapy. This prestigious conference features talks by key opinion leaders, invited to discuss new findings in the field of tumor immunology. Presentations cover both basic and translational research, highlighting rapidly developing advances in this breakthrough approach to cancer treatment.

CGEN-15001T and CGEN-15022 are both membrane proteins which were predicted and validated by Compugen as novel B7/CD28-like immune checkpoint candidates. Such checkpoint proteins are expressed on the surface of cancer cells and other cells within the tumor microenvironment, and their negative immune activities protect the tumor from being attacked by the immune system. Both Compugen targets have shown robust inhibitory activity in different assays of T cell activation, and in his talk, Dr. Levy presented some of these findings. The robust inhibitory activities of these novel immune checkpoints, which were previously demonstrated using each target's extracellular domain fused to an Fc antibody fragment, have now also been shown for the targets’ native membrane forms, which is an important finding for antibody targets.

In his talk, Dr. Levy presented expression profile data for CGEN-15001T and CGEN-15022 in various cancer types, demonstrating substantially different expression patterns for the two drug targets. As previously disclosed, CGEN-15001T is expressed in various solid cancers and hematological malignancies, including prostate cancer, melanoma, Hodgkin's lymphoma and Non-Hodgkin's lymphoma, such as T and B cell lymphomas. In addition, CGEN-15001T was shown to be expressed in the infiltrating immune cells within the tumor, further supporting an immunomodulatory role for this target in cancer development. In comparison, CGEN-15022 is highly expressed in liver, lung, breast, colorectal, prostate and ovarian cancers, as described today by Dr. Levy. The high expression levels observed in these cancers compared with their respective normal cells support the development of antibodies with high specificity toward the cancer cells.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.99 0.00%
FB $102.01 0.00%
GOOG $682.40 0.00%
TSLA $151.04 0.00%
YHOO $27.04 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs